
    
      The specific aims of this study are to test the hypotheses that the non-specific muscarinic
      antagonist tolterodine will not:- i) delay colonic transit and the proximal colonic emptying
      rate; ii) delay gastric emptying; nor iii) delay small intestinal transit compared to placebo
      in healthy subjects.
    
  